Br. J. Pharmacol. (1989), 96, 341-346

Release-regulating autoreceptors of the GABAB-type in human cerebral cortex Giambattista Bonanno *Paolo Cavazzani, *Gian Carlo Andrioli, Daniela Asaro, Graziella Pellegrini & tMaurizio Raiteri

Istituto di Farmacologia e Farmacognosia, Universita degli Studi di Genova, Viale Cembrano 4, 16148 Genova, Italy & *Divisione di Neurochirurgia, Ospedali Galliera, Via A. Volta 8, 16128 Genova, Italy

1 The depolarization-evoked release of y-aminobutyric acid (GABA) and its modulation mediated by autoreceptors were investigated in superfused synaptosomes prepared from fresh human cerebral cortex. 2 The release of [3H]-GABA provoked by 15 mmK+ from human cortex nerve endings was almost totally (85%) calcium-dependent. 3 In the presence of the GABA uptake inhibitor SK&F 89976A (N-4,4-diphenyl-3-butenyl)-nipe- cotic acid), added to prevent carrier-mediated homoexchange, GABA (1-10 pM) decreased in a concentration-dependent manner the K+-evoked release of [3H]-GABA. The effect of GABA was mimicked by the GABAB receptor agonist (-)- (1-100 pM) but not by the GABAA receptor agonist (1-100 uM). Moreover, the GABA-induced inhibition of [3H]-GABA release was not affected by two GABAA receptor antagonists, or SR 95531 (2-(3'-carbethoxy-2'- propenyl)-3-amino-6-paramethoxy-phenyl-pyridazinium ). 4 (-)-Baclofen also inhibited the depolarization-evoked release of endogenous GABA from human cortical synaptosomes. 5 It is concluded that GABA autoreceptors regulating the release of both newly taken up and endogenous GABA are present in human brain and appear to belong to the GABAB subtype.

Introduction Studies on the laboratory animal have shown that GABA in the rat brain of the GABAB receptor autoregulation of transmitter release mediated by subtype (Anderson & Mitchell, 1985; Pittaluga et al., receptors sited on the releasing terminals 1987; Waldmeier et al., 1988). (autoreceptors) appears to be a common feature of It has been proposed that abnormalities in GABA the major transmitter systems (Langer, 1981; Starke, transmission are associated with various human 1981; de Belleroche, 1982; Raiteri et al., 1984). Auto- disease states. The GABA system appears to be receptors for noradrenaline (for reviews see: Langer, altered in certain types of epilepsy (Meldrum, 1975), 1981; Starke, 1981), 5-hydroxytryptamine (Engel et in Huntington's and Parkinson's disease al., 1986; Maura et al., 1986; Bonanno et al., 1986) (Hornykiewicz et al., 1976; Schwarcz et al., 1977) and and acetylcholine (Marchi & Raiteri, 1985; Meyer & in a number of neuropsychiatric disorders including Otero, 1985; Mash & Potter, 1986) have been widely depression (Lloyd et al., 1985). studied and characterized in terms of types and sub- Due to this postulated involvement of GABA in types. In the case of y-aminobutyric acid (GABA) the neurological and psychiatric diseases and in view of mechanisms of autoregulation have been less investi- the existence of different types of GABA receptors gated. GABA autoreceptors have been reported to (Bowery, 1983) it was of relevance to determine: (a) be muscimol-sensitive (Mitchell & Martin, 1978; whether GABA autoreceptors are present in human Brennan et al., 1981) and therefore of the GABAA brain; (b) whether or not their pharmacological type. However a number of recent papers suggest the properties are similar to those of the autoreceptors presence of autoreceptors regulating the release of found in the rodent brain. We here show that func- tional autoreceptors belonging to the GABA, 'Author for correspondence. subtype are present in the cerebral cortex of man. © The Macmillan Press Ltd 1989 342 G. BONANNO et al.

Methods 6 min sample (evoked release). A 90 s period of depo- larization with 15 mM KCI was applied at the end of Characteristics ofhuman specimens the first fraction collected. GABA, (-)-baclofen or muscimol was added to the superfusion medium Samples of human cerebral cortex were obtained concomitantly with the depolarizing stimulus. from patients undergoing neurosurgery. The tissues Bicuculline, or the novel GABAA used were removed by the surgeon to reach deeply SR 95531 [2-(3'-carbethoxy-2'-propenyl)-3-amino-6- located tumours. The samples used represented parts paramethoxy-phenyl-pyridazinium bromide] (Wer- of frontal (2), temporal (3), parietal (2) and occipital muth & Biziere, 1986) was added 8 min before (2) lobes and were obtained from 5 female and 4 GABA. SK&F 89976A [4,4-diphenyl-3-butenyl)- male patients (aged 45-69 years). The tissues were nipecotic acid], a novel and potent inhibitor of obtained and processed separately on different days. GABA uptake (Yunger et al., 1984; Bonanno & After premedication with atropine and meperidine, Raiteri, 1987; Larsson et al., 1988) was present in the anaesthesia was induced with Pentothal and main- superfusion medium at a final concentration of 30 uM tained with 70% nitrous oxide in 30% oxygen and to minimize carrier-mediated exchange between 0.5-1% isoflurane. Pancuronium was employed to intraterminal [3H]-GABA or endogenous GABA obtain muscular relaxation. and extrasynaptosomal GABA or muscimol. Amino- oxyacetic acid (AOAA; final concentration 50pM) Preparation ofsynaptosomes was present throughout the experiment to prevent [3H]-GABA metabolism. AOAA was not used in Immediately after removal, the tissue was placed in a experiments on endogenous GABA release. physiological salt solution kept at 2-40C and a syn- Endogenous GABA in the superfusates was mea- aptosomal fraction was obtained within 60 min. sured with a radioreceptor assay, essentially as Crude synaptosomes were prepared essentially as described by Enna & Snyder (1976). High per- previously described (Gray & Whittaker, 1962) with formance liquid chromatography with fluorescent minor modifications. Briefly, the brain cortex was detection after pre-column derivatization by o- homogenized in 40 vol of 0.32M sucrose buffered at phathalaldehyde according to Tonnaer et al. (1983) pH 7.4 with phosphate using a glass-teflon tissue was applied in some cases. The results obtained did grinder (clearance 0.25 mm). The homogenate was not differ significantly from those obtained with the centrifuged (5 min, 0009g at 0-40C) to remove nuclei radioreceptor assay. At the concentration used in and debris and synaptosomes were isolated from the our experiments (-)-baclofen did not interfere in the supernatant by centrifugation at 12,000g for 20min. radioreceptor assay (Hill & Bowery, 1981). The synaptosomal pellet was then resuspended in a The amount of radioactivity released into each physiological medium having the following composi- fraction was expressed as the percentage of the tion (mM): NaCl 125, KCI 3, CaCl2 1.2, MgSO4 1.2, tritium content of synaptosomes at the start of the NaH2PO4 1, NaHCO3 22, glucose 10 (aerated with respective collection period. The depolarization- 95% 2 and 5% CO2 at 370C) pH 7.2-7.4. Protein evoked overflow was estimated by subtracting the was measured by the method of Petersen (1977). percent of tritium content of the basal release from the release evoked in the 6min fraction collected Release experiments during and after the depolarization pulse. The endogenous GABA released was expressed as pmol Synaptosomes were incubated in a rotatory water of amino acid per mg of synaptosomal protein. The bath at 37°C for 15min in the presence of 0.04.uM drug effects were evaluated as the ratio of the [3H]-GABA or without label (experiments on depolarization-evoked overflow calculated in the endogenous GABA release). After incubation, identi- presence of the drugs vs. that calculated under cal aliquots of the synaptosomal suspension (ranging control conditions. between 0.4-0.8mg protein in different experiments) were distributed on 0.65 pm Millipore filters placed Drugs at the bottom of a set of parallel superfusion cham- bers maintained at 37°C (Raiteri et al., 1974; Raiteri [3H]-GABA (105 Ci mmolP 1) was obtained from & Levi, 1978) and layered under moderate vacuum Amersham Radiochemical Centre; aminooxyacetic filtration. Superfusion was then started with stan- acid and (+)-bicuculline were purchased from Sigma dard medium aerated with 95% 02 and 5% CO2 at Chemical Co (St. Louis, MO, U.S.A.); GABA from a rate of 0.6mlmin-1 and continued for 48min. Serva (Heidelberg, F.R.G.). The following drugs were After 36 min to equilibrate the system, fractions were generous gifts by the companies indicated: (-)- collected according to the following scheme: two baclofen (Ciba Geigy, Basel, Switzerland); muscimol 3min samples (basal release) before and after one (Zambon Farmaceutici, Milan, Italy); SK&F 89976A GABAB AUTORECEPTORS IN HUMAN BRAIN 343

Table 1 Calcium-dependence of the K +-evoked release of [3H]-GABA from human cortical brain synaptosomes Standard mediuma Ca2+-free medium Basal release min -1 0.62 + 0.08 0.56 + 0.06 K + (15 mM)-evoked overflow 2.96 + 0.38 0.32 + 0.05* Values are the mean + s.e. mean of four experiments in triplicate. a Measured as percentage of total [3H]-GABA content. * Statistical significance of changes versus the K+ (15mM)-evoked overflow in standard medium were determined by Student's t test: P < 0.001.

(Smith Kline & French, Welwyn, England) and SR endogeneous GABA from human synaptosomes are 95531 (Sanofi, Bruxelles, Belgium). shown in Table 3. While the basal release was not significantly affected, the depolarization-evoked overflow was inhibited by about 50% when the Results agonist was present at 10 M. As shown in Table 1, when human cerebral cortex synaptosomes were exposed during superfusion to Discussion 15mM KCl, the depolarization-evoked release of tritium was almost totally calcium-dependent. The aims of this work were to ascertain the presence The Ca2+-dependency of the release, the presence of GABA autoreceptors in the human brain and to of 5OpM of the GABA transaminase inhibitor AOAA classify them in terms of GABA receptor subtype. throughout the experiment, the characteristics of the superfusion technique used (see Raiteri & Levi, +lor 1978), together with the data obtained previously in various laboratories (for review see Levi, 1984) make it likely that the radioactivity released by 15 mm KCl 0 E consisted largely of unmetabolized [3H]-GABA. 0 -v.i Therefore, in the remainder of the text, we refer to .0 the K+-evoked release of tritium as K+-evoked 10 [3H]-GABA release. Figure 1 shows that exogenous GABA (1-10pM), 0 added to the superfusion fluid, decreased in a concentration-dependent manner the K+-evoked Qi) 20- release of [3H]-GABA. The (-)-enantiomer of .a) baclofen produced a concentration-inhibition curve almost superimposable on that of GABA. In con- 30- trast, muscimol (1-100pM) was totally ineffective. Table 2 shows that neither (+)-bicuculline (10pM) I nor SR 95531 (10pM) was able to antagonize signifi- 40 cantly the inhibition of [3H]-GABA release caused - by an equimolar concentration of exogenous GABA. The results obtained when (-)-baclofen was tested -50L on both the basal and the K+-evoked release of I I I 1 3 10 30 100 Table 2 Effects of bicuculline and SR 95531 on the GABA-induced inhibition of the K'(15mM)- Drug concentration (pM) evoked release of [3H]-GABA Figure 1 Effects of y-aminobutyric acid (GABA, (Q), (-)-baclofen (@) or muscimol (U) on the release of % inhibition [3H]-GABA evoked by depolarization of human brain cortical synaptosomes. When GABA was used as an GABA 10puM 40.4 + 2.9 agonist, SK&F 89976A 30pM, an inhibitor of GABA GABA 1OpM + bicuculline 10pM 41.2 ± 2.8 uptake was added to the superfusion medium. Amino- GABA 10pM + SR 95531 10pM 37.8 + 3.2 oxyacetic acid (50M) was present throughout the experiment to prevent [3H]-GABA metabolism; Points Values are the mean + s.e.mean of 4-6 experi- represent the mean of 3-4 separate experiments with ments in triplicate. s.e.mean shown by vertical lines. 344 G. BONANNO et al.

Table 3 Effect of (-)-baclofen (10pM) on the K+-evoked release of endogenous GABA from human cortical brain synaptosomes Controls? (-)-Baclofen Basal release min -1 28.3 + 3.2 25.2 + 2.7 K+ (15 mm)-evoked overflow 149.6 + 21.7 76.7 + 11.5* Values are the mean + s.e.mean of five experiments in triplicate. * Measured as pmol of endogenous GABA released mg 1 protein. * Statistical significance of changes versus controls were determined by Student's t test: P < 0.05.

When studying release-regulating autoreceptors, a ceptors in human cerebral cortex belong to the critical point is to show that the natural transmitter GABAB subtype. A note of caution is necessary, is able to depress its own release from nerve term- however, because potent and selective GABAB recep- inals. In the case of GABA this has always been a tor antagonists have not been available. Only recent- problem due to the fact that exogenous GABA, used ly, it has been proposed that the phosphonic acid as an autoreceptor agonist, stimulates very actively derivative of baclofen (phaclofen) is an antagonist at the release of the radioactive GABA used to label the GABAB receptor on the basis of electrophysiological nerve terminals through an homoexchange process studies (Kerr et al., 1987; Dutar & Nicoll, 1988). In (Levi & Raiteri, 1974). This exchange obviously preliminary experiments, phaclofen partly antago- obscures the expected inhibitory effect of the natural nized the action of GABA on [3H]-GABA release transmitter unless a very efficient blocker of the (data not shown). GABA carrier is present. The novel compound used As to the anatomical localization of the GABAB in this study (SK&F 89976A) is a potent and selec- receptor regulating GABA release, the experimental tive inhibitor of the uptake of GABA (Yunger et al., set up used (a thin layer of synaptosomes in 1984; Bonanno & Raiteri, 1987). Moreover, SK&F superfusion) should exclude the possibility that we 89976A is a pure GABA uptake inhibitor devoid of are dealing with somato-dendritic autoreceptors. It intrinsic releasing activity (data not shown). The should be added that indirect effects involving trans- compound is therefore different from other uptake mitters other than GABA are minimized by use of inhibitors such as nipecotic acid which is known also the above technique (see Raiteri & Levi, 1978 for to be a substrate for the GABA uptake system and more details). Moreover, it has been reported that to release [3H]-GABA through a heteroexchange neuronal but not glial release of [3H]-GABA was process (Szerb, 1983). Thus, SK&F 89976A appears stimulated by K+ depolarization (Neal & Bowery, to be particularly suitable for studying GABA auto- 1979). These considerations, together with the receptors when the natural transmitter is used as an calcium-dependency of the release of GABA (which agonist. Our data show that, in the presence of is generally taken as an indication of a neuronal SK&F 89976A, GABA inhibited the K+-evoked origin of the transmitter released) make it legitimate release of [3H]-GABA, indicating that autoreceptors to conclude that the human GABA autoreceptors involved in the regulation of [3H]-GABA release characterized in this study are sited on GABA- exist on the GABA nerve terminals of human cere- releasing nerve terminals. bral cortex. Considering that newly taken up radioactive It is now well accepted that GABA receptors exist GABA may in some cases behave differently from in two different types, termed GABAA and GABAB the endogenously synthesized amino acid (see Szerb, (Bowery, 1983). It has been proposed that the latter 1983), we tested the effect of baclofen on the release type inhibits the stimulus-evoked release of several of endogenous GABA. The finding that (-)-baclofen transmitters (Bowery et al., 1980). The receptor inhibited not only the release of previously taken up involved in the autoinhibition of GABA release was [3H]-GABA but also that of endogenous GABA characterized by using various pharmacological strengthens the idea that GABAB autoreceptors are tools. The findings that: (a) the effect of GABA was present on GABAergic nerve endings in human insensitive to the GABAAreceptor antagonists (+)- cerbral cortex. bicuculline or SR 95531 (Wermuth & Biziere, 1986); Finally, when the present results in human brain (b) muscimol, a GABAA receptor agonist, did not cortex are compared with those obtained in the cere- mimic the effect of GABA and (c) the GABAB recep- bral cortex of the rat (Pittaluga et al., 1987), no clear tor agonist (-)-baclofen (Bowery et al., 1980) pro- differences appear to exist between the release- duced a dose-dependent inhibition of [3H]-GABA regulating GABA autoreceptors present in the two release, allow us to suggest that the GABA autore- species. Actually, the effects of GABA and (-)-baclo- GABAB AUTORECEPTORS IN HUMAN BRAIN 345 fen are strikingly similar in man and rat. As an This work was supported by grants from the Italian Minis- important consequence, the laboratory animal try of Education, from the Italian National Research appears to be a useful model for studying GABAB Council and from Regione Liguria. The authors thank Mrs autoreceptors and for testing new drugs of potential Maura Agate for typing the manuscript. therapeutic use.

References

ANDERSON, R.A. & MITCHELL, R. (1985). Evidence for LARSSON, O.M., FALCH, E., KROGSGAARD-LARSEN, P. & GABAB autoreceptors in median eminence. Eur. J. SCHOUSBOE, A. (1988). Kinetic characterization of inhi- Pharmacol., 118, 355-358. bition of y-aminobutyric acid uptake into cultured BONANNO, G., MAURA, G. & RAITERI, M. (1986). Pharma- neurons and astrocytes by 4,4-diphenyl-3-butenyl deriv- cological characterization of release-regulating seroton- atives of nipecotic acid and guvacine. J. Neurochem., 50, in autoreceptors in rat cerebellum. Eur. J. Pharmacol., 818-823. 126, 317-321. LEVI, G. & RAITERI, M. (1974). Exchange of neurotransmit- BONANNO, G. & RAITERI, M. (1987). Coexistence of car- ter amino acid at nerve endings can simulate high affin- riers for dopamine and GABA uptake on a same nerve ity uptake. Nature, 250, 735-737. terminal in the rat brain. Br. J. Pharmacol., 91, 237-243. LEVI, G. (1984). Release of putative transmitter amino acids. BOWERY, N.G., HILL, D.R., HUDSON, A.L., DOBLE, A., In Handbook of Neurochemistry. vol. 6. ed. Lajtha, A. MIDDLEMISS, D.N., SHAW, J. & TURNBULL, M. (1980). pp. 463-509. New York: Plenum Press. (-)-Baclofen decreases neurotransmitter release in the LLOYD, K.G., THURET, F. & PILC, A. (1985). Upregulation mammalian CNS by an action at a novel GABA recep- of GABAB binding sites in rat frontal cortex: a common tor. Nature, 283, 92-94. action of repeated administration of different classes of BOWERY, N.G. (1983). Classification of GABA receptors. In antidepressants and electroschock. J. Pharmacol. Exp. The GABA Receptors. ed. Enna, S.J. pp. 177-213. Ther., 235, 191-199. Clifton, N.J.: Humana Press. MARCHI, M. & RAITERI, M. (1985). On the presence in the BRENNAN, M.J.W., CANTRILL, R.C., OLDFIELD, M. & cerebral cortex of muscarinic receptor subtypes which KROGSGAARD-LARSEN, P. (1981). Inhibition of y- differ in neuronal localization, function and pharmacol- aminobutyric acid release by y-aminobutyric acid ogical properties. J. Pharmacol. Exp. Ther., 235, 230- agonist drugs. Pharmacology of the y-aminobutyric 233. acid autoreceptor. Mol. Pharmacol., 19, 27-30. MASH, D.C. & POTTER, L.T. (1986). Autoradiographic local- DE BELLEROCHE, J. (1982). Presynaptic Receptors. Chich- ization of M1 and M2 muscarine receptors in the rat ester, England: Ellis Horwood Limited. brain. Neuroscience, 19, 551-564. DUTAR, P. & NICOLL, R.A. (1988). A physiological role for MAURA, G., ROCCATAGLIATA, E. & RAITERI, M. (1986). GABA5 receptors in the central nervous system. Nature, Serotonin autoreceptor in rat hippocampus: pharma- 332, 156-158. cological characterization as a subtype of the 5-HT1 ENGEL, G., GOTHERT, M., HOYER, D., SCHLICKER, E. & receptor. Naunyn-Schmiedebergs Arch. Pharmacol., 334, HILLENBRAND, K. (1986). Identity of inhibitory presy- 323-326. naptic 5-hydroxytryptamine (5-HT) autoreceptors in the MELDRUM, B.S. (1975). Epilepsy and y-aminobutyric acid- rat brain cortex with 5-HT1B binding sites. Naunyn- mediated inhibition. Int. Rev. Neurobiol., 17, 1-36. Schmiedebergs Arch. Pharmacol., 332, 1-7. MEYER, E.M. & OTERO, D.H. (1985). Pharmacological and ENNA, S.J. & SNYDER, S.H. (1976). A simple sensitive and ionic characterizations of the muscarinic receptors specific radioreceptor assay for endogenous GABA in modulating 3H-acetylcholine release from rat cortical brain tissue. J. Neurochem., 26, 221-224. synaptosomes. J. Neurosci., 5, 1202-1207. GRAY, E.G. & WHIT-AKER, V.P. (1962). The isolation of MITCHELL, P.R. & MARTIN, I.L. (1978). Is GABA release nerve endings from brain: an electron-microscopic modulated by presynaptic receptors? Nature, 274, 904- study of cell fragments derived by homogenization and 905. centrifugation. J. Anat., 96, 79-87. NEAL, M.J. & BOWERY, N.G. (1979). Differential effects of HILL, D.R. & BOWERY, N.G. (1981). 3H-baclofen and veratridine and potassium depolarization on neuronal 3H-GABA bind to bicuculline-insensitive GABA5 sites and glial GABA release. Brain Res., 167, 337-343. in rat brain. Nature, 290, 149-152. PETERSEN, G.L. (1977). A simplification of the protein HORNYKIEWICZ, O., LLOYD, K.G. & DAVIDSON, L. (1976). assay method of Lowry et al. which is more generally The GABA system, function of the basal ganglia, and applicable; Anal. Biochem., 83, 346-356. Parkinson's disease. In GABA in Nervous System Func- PITTALUGA, A., ASARO, D., PELLEGRINI, G. & RAITERI, M. tion. ed. Roberts, E., Chase, T.N. & Tower, D.B. pp. (1987). Studies on 3H-GABA and endogenous GABA 479-485. New York: Raven Press. release in rat cerebral cortex suggest the presence of KERR, D.I.B., ONG, J., PRAGER, R.H., GYNTHER, B.D. & autoreceptors of the GABAB type. Eur. J. Pharmacol., CURTIS, D.R. (1987). Phaclofen: a peripheral and central 144,45-52. baclofen antagonist. Brain Res., 405, 150-154. RAITERI, M., ANGELINI, F. & LEVI, G. (1974). A simple LANGER, S.Z. (1981). Presynaptic regulation of the release apparatus for studying the release of neurotransmitters of catecholamines. Pharmacol. Rev., 32, 337-362. from synaptosomes. Eur. J. Pharmacol., 25, 411-414. 346 G. BONANNO et al.

RAITERI, M. & LEVI, G. (1978). Release mechanisms for Proteolytic conversion of angiotensins in rat brain catecholamines and serotonin in synaptosomes. In tissue. Eur. J. Biochem., 131, 415-421. Reviews of Neuroscience, vol. 3. ed. Ehrenpreis, S. & WALDMEIER, P.C., WICKI, P., FELDTRAUER, J.-J. & Kopin, I. pp. 77-130. New York: Raven Press. BAUMANN, P.A. (1988). Potential involvement of a RAITERI, M., MARCHI, M. & MAURA, G. (1984). Release of baclofen-sensitive autoreceptor in the modulation of the catecholamines, serotonin, and acetylcholine from iso- release of endogenous GABA from rat brain slices in lated brain tissues. In Handbook ofNeurochemistry, vol. vitro. Naunyn-Schmiedebergs Arch. Pharmacol., 337, 6. ed. Lajtha, A. pp. 431-462. New York: Plenum Press. 289-295. SCHWARCZ, R., BENNET, J.P. & COYLE, J.T. (1977). Inhibi- WERMUTH, C.G. & BIZItRE, K. (1986). Pyridazinyl-GABA tors of GABA metabolism: implications for Hunt- derivatives: a new class of synthetic GABAA antago- ington's disease. Ann. Neurol., 2, 299-305. nists. Trends Pharmacol. Sci., 7, 421-424. STARKE, K. (1981). Presynaptic receptors. Ann. Rev. Phar- YUNGER, L.M., FOWLER, P.J., ZAREVICS, P. & SETLER, P.E. macol. Toxicol., 21, 7-30. (1984). Novel inhibitors of y-aminobutyric acid (GABA) SZERB, J.C. (1983). The release of 3H-GABA formed from uptake: anticonvulsant actions in rats and mice. J. 3H-glutamate in rat hippocampal slices: comparison Pharmacol. Exp. Ther., 228, 109-115. with endogenous and exogenous labeled GABA. Neuro- chem. Res., 8, 341-351. TONNAER, J.A.D.M., ENGELS, G.H.M., WIEGANT, V.M., BURBACH, J.P.H., DE JONG, W. & DE WIED, D. (1983). (Received July 29, 1988 Revised September 21, 1988 Accepted September 23, 1988)